Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus johnsonii has some scientific evidence supporting its use in the management and prevention of ulcers, particularly those associated with Helicobacter pylori infection. Several in vitro and animal studies have demonstrated that L. johnsonii can inhibit the growth and colonization of H. pylori, a primary causative agent of peptic ulcers. The proposed mechanisms include the production of lactic acid and bacteriocins, competition for mucosal binding sites, and modulation of local immune responses to reduce gastric inflammation. A limited number of small clinical trials have explored the adjunctive use of L. johnsonii with standard antibiotic therapy for H. pylori eradication. While these studies suggest a potential benefit—such as improved eradication rates and reduced gastrointestinal side effects—the sample sizes are generally small and results are not always consistent. There is not yet robust, large-scale clinical evidence to firmly establish L. johnsonii as a standalone or primary therapy for ulcers. In summary, the use of Lactobacillus johnsonii for ulcers is supported by preliminary scientific research, especially in the context of H. pylori-associated ulcers, but current evidence is limited and further high-quality clinical trials are needed to confirm efficacy.

More about Lactobacillus johnsonii
More about Ulcers

Other ingredients used for Ulcers

Other health conditions supported by Lactobacillus johnsonii

Products containing Lactobacillus johnsonii